Prosecution Insights
Last updated: November 15, 2026
Application No. 18/037,461

PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF

Non-Final OA §103§112
Filed
May 17, 2023
Priority
Nov 19, 2020 — provisional 63/115,749 +3 more
Examiner
DAHLIN, HEATHER RAQUEL
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zevra Denmark A/S
OA Round
3 (Non-Final)
42%
Grant Probability
Moderate
3-4
OA Rounds
88%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
70 granted / 167 resolved
-18.1% vs TC avg
Strong +46% interview lift
Without
With
+46.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
47 currently pending
Career history
229
Total Applications
across all art units

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on April 21, 2026 has been entered. Priority This Application is a 371 of PCT/EP2021/082294, filed Nov. 19, 2020 and claims provisional benefit of U.S. Provisional Application nos. 63/115,749 and 63/211,809, filed Nov. 19, 2020 and June 17, 2021, and foreign priority to EP20209467.8, filed Nov. 24, 2020 with the EPO. Claim Status Claims 158 and 174-180 are currently pending and subject to examination. Claim Rejections – Withdrawn – Overcome by Amendment The rejection of claim(s) 174 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn. The rejection of claim(s) 175 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends is withdrawn. The rejection of claim(s) 158-159 under 35 U.S.C. 103 as being unpatentable over Urogdi et al. (US 7,126,002 B2, Published Oct. 24, 2006) is withdrawn. The rejection of claim(s) 158-159 and 174 under 35 U.S.C. 103 as being unpatentable over Urogdi et al. (US 7,126,002 B2, Published Oct. 24, 2006), as applied to claims 158-159 above, and further in view of Atkinson et al. (Organic & Biomolecular Chemistry, Vol. 15, 2017, p. 9794-9799) (of record) is withdrawn. The above rejections were overcome by Applicant’s amendments to the claims. Claim Rejections – 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): “(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.” The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: “The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” Claims 158, 176 and 179-180 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 158 recites the limitation "the mixture" in the second to last line. There is insufficient antecedent basis for this limitation in the claim. Step 3 does not recite a mixture, but rather only recites precipitating arimoclomol with L-DBTA to provide the L-DBTA salt of arimoclomol. It is unclear if “the mixture” refers to the combination of arimoclomol and DBTA prior to crystallization, a solution from which the salt is precipitated or the suspension of precipitated salt in its mother liquor. Appropriate correction is required. Claim Rejections – 35 USC § 103 – New Grounds of Rejection Necessitated by Amendment The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: “A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.” The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 158 and 174-180 is/are rejected under 35 U.S.C. 103 as being unpatentable over Urogdi et al. (US 7,126,002 B2, Published Oct. 24, 2006) in view of Aufdenblatten et al. (US 7,816,545 B2) and Prashad & Har (US 6,100,401 A). Claim 158 is directed towards a process for preparing PNG media_image1.png 88 179 media_image1.png Greyscale comprising: Mixing a compound of formula (I) PNG media_image2.png 91 162 media_image2.png Greyscale with a compound of formula (II) PNG media_image3.png 60 168 media_image3.png Greyscale in a polar protic solvent or a mixture of polar protic solvents and at a temperature between about 70°C to 100°C; Wherein the intermediate formed during step 1 is then reacted with sodium nitrite in a solvent that is a chlorinated hydrocarbon, a mixture containing at least one chlorinated hydrocarbon or a combination thereof and at a temperature of about 0°C to 15°C; Precipitating PNG media_image1.png 88 179 media_image1.png Greyscale with dibenzoyl-L-tartaric acid to provide: PNG media_image4.png 138 202 media_image4.png Greyscale reacting PNG media_image4.png 138 202 media_image4.png Greyscale with at least one base to form the free base of PNG media_image4.png 138 202 media_image4.png Greyscale and precipitating the free base of PNG media_image4.png 138 202 media_image4.png Greyscale with citric acid to provide arimoclomol citrate, wherein step 3 comprises cooling the mixture at a cooling rate between about 15 K/h and about 50 k/h. Urogdi discloses a substantially identical process comprising similar steps 1 and 2: PNG media_image5.png 19 88 media_image5.png Greyscale Urogdi, Figs. 1-5; “FIG. 1 shows the compound of formula (I): N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine. FIG. 2 shows the compound of formula (II): 3-cyano-pyridine-1-oxide. FIG. 3 shows the compound of formula (III): 3-pyridine-amidoxim-1-oxide. FIG. 4 shows the compound of formula (IV): 2-hydroxy-4-azoniaspiro[3,5]nonane chloride. FIG. 5 shows the compound of formula (V): N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.” Urogdi, Specification, col. 1-2; PNG media_image6.png 357 374 media_image6.png Greyscale Urogdi, Specification, col. 5; PNG media_image7.png 135 369 media_image7.png Greyscale PNG media_image8.png 239 387 media_image8.png Greyscale Urogdi, Specification, col. 5-6. The above example 3 is substantially identical to step 1. Urogdi teaches that PNG media_image5.png 19 88 media_image5.png Greyscale is reacted with PNG media_image5.png 19 88 media_image5.png Greyscale in a mixture of polar protic solvents, water and ethanol, at reflux temperature which must be between 78°C and 100°C, which are the boiling points of ethanol and water respectively. The above example 4 is substantially identical to step 2. Urogdi teaches that the intermediate prepared during step 1 is reacted with sodium nitrite in an aqueous solution alkalified with sodium hydroxide at a temperature -5°C to 0°C and less than 7°C and then extracted three times with dichloromethane. The temperatures of -5°C to 0°C and less than 7°C overlaps with the range of 0°C to 15°C and therefore the claimed temperature range is prima facie obvious. See MPEP § 2144.05. While Urogdi does not teach that the reaction is carried out in a mixed solvent of water and dichloromethane as in the instant application, one of ordinary skill in the art would have a reasonable expectation of success to carry out the reaction in a mixed solvent of water and dichloromethane because Urogdi teaches extraction with dichloromethane. Dichloromethane and water are immiscible and therefore products and reactants can be separated in different liquid layers. For step 3, Urogdi teaches a process which is substantially identical to the claimed process wherein the product from Urogdi example 4 is used as a substrate in example 5, reacted with dibenzoyl-L-tartaric acid to provide the dibenzoyl-L-tartrate salt of the compound, which is reacted with potassium carbonate to form the free base, which is reacted with citric acid to provide arimoclomol citrate : PNG media_image9.png 132 367 media_image9.png Greyscale PNG media_image10.png 243 357 media_image10.png Greyscale PNG media_image11.png 195 385 media_image11.png Greyscale PNG media_image12.png 199 314 media_image12.png Greyscale PNG media_image13.png 472 306 media_image13.png Greyscale Urodgi, Specification, col. 6-9. Urodgi establishes the (R)-arimoclomol salt of (-)-dibenzoyl-L-tartaric acid (L-DBTA) forms and selectively crystallizes from ethanol, giving the (R)-enantiomer with high optical purity (96% or greater). Thus, the resolving agent, solvent and diastereomeric salt of the claimed process were already known for arimoclomol. Urodgi teaches dissolution in ethanol and crystallization at room temperature. The only modification in the claimed application is the cooling profile used to crystallize that salt. While Urodgi does not teach the cooling profile, one of ordinary skill in the art would have a reasonable expectation of success to modify the crystallization process and heat the solution for dissolution and cool the solution at a rate of 15-50 K/h (15-50 °C/h) because this is a commonly known method for chiral resolution of basic amines with L-DBTA. Aufdenblatten teaches this method for the chiral resolution of a racemic amine (compound (III)) with L-DBTA in aqueous ethanol. The mixture is heated to 70°C to dissolve the solids, then cooled to room temperature over 3 hours, a cooling rate of about 15-17 °C/h (70°C -20°C /3 h ~ 17°C/h; 70°C -25°C /3 h = 15°C/h). This gives the L-DBTA salt in 98.4% de: PNG media_image14.png 308 302 media_image14.png Greyscale Aufdenblatten, Specification, col. 5, ex. 3. Likewise, Prashad teaches crystallizing optically enriched DBTA salts of an amine, methylphenidate, from an aqueous alcohol by cooling from about 40° to 45 °C to a temperature between 20° and 25° C over a period of 1 hour (15-25 °C/h), then cooling from 20° and 25° C to a temperature between 0° and 5° C over a period of 15 minutes (60 - 100 ° C/h) to obtain the desired enantiomer at high optical purity (99.36:0.64): PNG media_image15.png 94 296 media_image15.png Greyscale PNG media_image16.png 428 314 media_image16.png Greyscale Prashad, Specification, col. 4-5; PNG media_image17.png 290 300 media_image17.png Greyscale Prashad, Specification, col. 6. Urodgi shows that arimoclomol, like the compounds resolved in Aufdenblatten and Prashad, is a basic amine that forms acid addition salts, including with L-DBTA. Aufdenblatten and Prashad demonstrate that cooling rates within the claimed range reliably crystallize DBTA diastereomeric salts of such amines from alcoholic solvents with high diastereomeric purity. Accordingly, applying the cooling profiles of Aufdenblatten and Prashad to the resolution process of Urodgi is the use of a known technique to improve a method in the same way, with predictable results. See KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 417 (2007); MPEP § 2143(I)(C)-(D). Therefore, claim 158 was prima facie obvious at the time of filing. Claim 174 is directed towards the process of claim 158, wherein the arimoclomol having formula I is present in a stereoisomeric quantity of greater than 98% (R)-arimoclomol. Urogdi teaches that N-{[(2R)-2-hydroxy-3-piperidin-1- ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide can be obtained with an optical purity of at least 96%: PNG media_image18.png 342 592 media_image18.png Greyscale Urogdi, Specification, col. 9; PNG media_image19.png 141 592 media_image19.png Greyscale Urogdi, Specification, col. 2. A purity of at least 96% is very close to and overlaps with a purity of at least 98% and therefore a prima facie case of obviousness exists. See MPEP § 2144.05. One of ordinary skill in the art would further have a reasonable expectation of success of obtaining (R)-arimoclomol with an optical purity of at least 98% because DBTA diastereomeric salts crystallized at cooling rates within the claimed range were known to have optical purities of 98% or greater: 98.4% de at about 15-17 °C/h (Aufdenblatten, Ex. 3), and an enantiomer ratio of 99.36:0.64 at about 15-25 °C/h (Prashad, Ex. 3). Optical purity is therefore a result-effective variable that one of ordinary skill in the art would have optimized through routine adjustment of known parameters, including cooling rate, which a reasonable expectation of success of obtaining at least 98% optical purity. See MPEP 2144.05(II). Therefore, claim 159 was prima facie obvious at the time of filing. Claim 176 is directed towards the process of claim 158, wherein the cooling rate is between about 15 °K/h and about 30 °K/h. The rejection of claim 158 is incorporated herein by reference, showing that cooling rates between about 15-30 °K/h are commonly known in the art. Therefore, claim 176 was prima facie obvious at the time of filing. Claim 177 is directed towards the process of claim 158, wherein step 3 is carried out in a mixture of polar protic solvents selected from the group consisting of water, ethanol, methanol, and 2-propanol. Claim 178 is directed towards the process of claim 177, wherein the mixture is a mixture of ethanol and water. As shown in the rejection of claim 158, Urodgi teaches that the solvent is ethanol. One of ordinary skill in the art would have a reasonable expectation of success to use a mixture of polar protic solvents because such crystallization conditions are commonly known in the art. For example, Aufdenblatten teaches a mixture of water/ethanol (Aufdenblatten, Ex. 3) and Prashad teaches a mixture of methanol and water (Prashad, Ex. 1/3). Therefore, claims 177-178 were prima facie obvious at the time of filing. Claim 179 is directed towards the process of claim 158, wherein step 3 further comprises heating the mixture to a temperature between about 65 °C to about 70 °C. While Urodgi does not teach to heat the mixture to a temperature between about 65 °C to about 70 °C, one of ordinary skill in the art would have a reasonable expectation of success to heat the mixture to a temperature between about 65 °C to about 70 °C because this is a common step used in DBTA mediated chiral resolution to dissolve substances in a mixture of polyprotic solvents prior to crystallization. For example, Aufdenblatten teaches to heat the mixture of water/ethanol, compound and DBTA to 70 °C to dissolve the solids (Aufdenblatten, Ex. 3). Therefore, claim 179 was prima facie obvious at the time of filing. Claim 180 is directed towards the process of claim 158, wherein step 3 further comprises cooling the mixture to about 20 °C. As shown in the rejection of claim 158, Urodgi teaches crystallization at room temperature (20-25 °C). While Urodgi does not teach cooling the mixture, one of ordinary skill in the art would have a reasonable expectation of success to cool the mixture to about 20 °C because this is a common step used in DBTA mediated chiral resolution to crystallize the desired enantiomer. For example, Aufdenblatten teaches to cool the mixture of water/ethanol, compound and DBTA to room temperature (20-25 °C). Therefore, claim 180 was prima facie obvious at the time of filing. Given the above teachings, the invention as a whole was prima facie obvious at the time of filing. Conclusion No claim is found to be allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HEATHER DAHLIN whose telephone number is (571)270-0436. The examiner can normally be reached 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached on (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 86-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HEATHER DAHLIN/Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

May 17, 2023
Application Filed
Sep 04, 2025
Non-Final Rejection mailed — §103, §112
Dec 04, 2025
Response Filed
Jan 21, 2026
Final Rejection mailed — §103, §112
Apr 21, 2026
Request for Continued Examination
Apr 23, 2026
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773407
Methods of Managing Cocaine or Other Drug Addictions
3y 8m to grant Granted Oct 27, 2026
Patent 12760023
CYCLIN-DEPENDENT KINASE INHIBITORS
5y 3m to grant Granted Oct 13, 2026
Patent 12753174
CRYSTALLINE FORM OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR
3y 0m to grant Granted Oct 06, 2026
Patent 12729193
TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4
3y 4m to grant Granted Sep 08, 2026
Patent 12703686
4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME
3y 4m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
42%
Grant Probability
88%
With Interview (+46.0%)
High
PTA Risk
Based on 167 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month